|Dr. Mitchel B. Sayare||Exec. Chairman||165.42k||N/A||1948|
|Dr. Vipin K. Garg||Pres, CEO & Director||143.62k||N/A||1958|
|Mr. William Michael Brown||CFO & Principal Accounting Officer||216k||N/A||1982|
|Dr. Sybil Tasker||Consultant||529.63k||N/A||1963|
|Mr. Bertrand Georges Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, discovers and develops immunotherapies and vaccines to address the unmet medical needs. The company develops HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus that completed the Phase I clinical trial; NasoVAX, an intranasally administered recombinant influenza vaccine that completed Phase 2a clinical trials; and NasoShield, an anthrax vaccine for protection after a single intranasal administration that is in Phase I clinical trial. Its preclinical stage products include ALT-702, a tumor immunostimulant product candidate for treating cancer; and ALT-801, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.